MP54-13 BLUE LIGHT IN COMBINATION WITH HEAMINOLEVULINATE (CYSVIEW®) LEADS TO BLADDER CANCER CELL DEATH IN AN IN VITRO MODEL (2018)

You have accessJournal of UrologyBladder Cancer: Basic Research & Pathophysiology I1 Apr 2018MP54-13 BLUE LIGHT IN COMBINATION WITH HEAMINOLEVULINATE (CYSVIEW®) LEADS TO BLADDER CANCER CELL DEATH IN AN IN VITRO MODEL Justin T. Matulay, Alanna B. Williams, Mark V. Silva, James M. McKiernan, and Michael M. Shen Justin T. MatulayJustin T. Matulay More articles by this author , Alanna B. WilliamsAlanna B. Williams More articles by this author , Mark V. SilvaMark V. Silva More articles by this author , James M. McKiernanJames M. McKiernan More articles by this author , and Michael M. ShenMichael M. Shen More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.1704AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Blue light cystoscopy with hexaminolavulinate (HAL, Cysview®) improves detection of bladder cancer over white light cystoscopy alone, and has been FDA-approved for this purpose. Photodynamic therapy (PDT) is used as a treatment for various malignancies, but aside from some small phase I trials, has not been utilized in treatment of bladder cancer. The purpose of this study was to measure the cell death effect of HAL/Blue light on patient-derived bladder cancer organoids. METHODS Fresh bladder cancer specimens were collected as part of an IRB approved protocol (AAAN8850) and grown as 3D bladder cancer organoids per lab protocol. Organoids were treated with saline 100uM, HAL 10uM, HAL 100uM, camptothecin 10uM, or camptothecin 100uM, then incubated for 4 hours. One group of HAL treated organoids at each drug concentration was exposed to blue light while the groups remained in the incubator. The blue light source was calibrated to deliver a peak wavelength of 410nm at an energy of 1J/cm2. Cell viability was assessed using the Promega CellTiter-Glo® luminescent cell viability assay at 18 hours and caspase-3 activity was assessed on histologic specimens at 6, 12, and 18 hours. RESULTS Bladder cancer organoid cell viability was significantly reduced by 95% and 97% for HAL+Blue Light treated organoids at drug concentrations of 10uM and 100uM, respectively. HAL treatment alone reduced cell viability by 19% and 21% for concentrations of 10uM and 100uM, respectively. P-value < 0.0001 for all comparison groups (figure). Histologic staining for caspase-3 was sparse and did not show significant difference between saline controls, HAL alone, or HAL+Blue Light treated organoids but was increased in the camptothecin treated group. CONCLUSIONS The combination of HAL and Blue Light drastically reduces cell survival in patient-derived bladder cancer organoids. These results suggest that beyond the diagnostic utility of Blue Light Cystoscopy with HAL there is a potential for therapeutic benefit. Further investigation into the apoptotic pathway is warranted based on IHC staining results. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e716-e717 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Justin T. Matulay More articles by this author Alanna B. Williams More articles by this author Mark V. Silva More articles by this author James M. McKiernan More articles by this author Michael M. Shen More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...